TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction in alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inguinal dehiscence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Lymphocele rate
Endpoint domain: Adverse events/effects
Primary endpoint: 24-hour frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPSS storage score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: six-month survival
Endpoint domain: Mortality/survival
Primary endpoint: Rate of vesicoureteral leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of obstruction
Endpoint domain: Adverse events/effects
Primary endpoint: office systolic blood pressure (oSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour ambulatory systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recipient satisfaction with the intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Posttraumatic stress disorder symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in visual acuity letter score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative probability of cataract surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intraocular pressure increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Reduction in bladder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NGF mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in oral lichen planus symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSQI total score improvement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Use of sleep medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ESS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: overall cancer risk
Endpoint domain: Mortality/survival
Primary endpoint: 6.5-year risk of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: well-being of institutionalized aged persons
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Densities of melanocytic nevi (MN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Compliance with bracing recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Costs associated with treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Functional outcomes (motion deficit and straight leg raise strength)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life sub-scale of the KOOS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Visual analog scale (VAS) severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sexual-function-related treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal Hb levels at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elective caesarean section rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Infant birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: viral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotective titer (HI ≥ 1:40)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum hsCRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of measures taken per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of DMARD therapy change
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ability to achieve orgasm
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Reduction of low back pain (LBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory index after cardiopulmonary bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Measured granulocyte elastase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Suicide attempt
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of HEV
Endpoint domain: Mortality/survival
Primary endpoint: Blood Glucose Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lactate Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NRS‐11 Panda score after emergence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS‐100 Panda score upon meeting discharge criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in access and use of primary care health services
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Quality of the consumer-physician relationship
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased confidence in consumer self-management of healthcare
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Seroresponse against rabies (RFFIT titre⩾0.5IU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Isometric muscle strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dynamic muscle strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: BMD of the hip increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: new vertebral fracture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: fracture-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean spinal bone mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the plasma concentration-time curve (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of incidents involving mechanical restraints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of Barrett's epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apoptotic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of pantoprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion rate on AFL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall conversion rate on AFL and AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Rate Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Myocardial Ischemia or Infarction
Endpoint domain: Adverse events/effects
Primary endpoint: pathologically increased platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean concentration of platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: platelet yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thirty-day point prevalence abstinence
Endpoint domain: Mortality/survival
Primary endpoint: Food choices (meats/proteins consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food choices (sweets consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food choices (pizza/fast food consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cannabis use frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transition from non-user to cannabis use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apical sealing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: canal-filled area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma total lycopene concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Milk total lycopene concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean BPRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extrapyramidal symptoms (EPS)
Endpoint domain: Adverse events/effects
Primary endpoint: locoregional disease-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: minutes of at least moderate intensity physical activity per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Medication barrier scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual analogue scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Poor survival linked to IL-11 levels
Endpoint domain: Mortality/survival
Primary endpoint: Mean change in HbA1c values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median number of ARTIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median duration of illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median number of missed school days due to an ARTI
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: PASI 90 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ox‐LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary F2‐isoprostanes (8‐iso‐prostaglandin F2α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of cocaine-negative samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in psychosocial functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: distress slope
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: median global score on perceived information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: satisfaction with information received
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: memory recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: memory discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: motor speed and dexterity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients achieving remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha-amylase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Daily median crying time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less stressed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer defining characteristics of Disorganized Infant Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: More suitable position for receiving intensive care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNOT-20 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of postprocedure debridements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: relative %VP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax values for AQ and DSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUC0-t values for AQ and DSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tmax values for AS and DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Venous Reflux Time (VRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of 10-min time windows containing high-amplitude propagated contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the curve per 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fighting Spirit
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive Avoidance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: stones cleared at first ERCP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of complex perceptual-motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of venous morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about suicide
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitudes towards suicidal persons
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevention of clinical prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Prevention of prostatic cancer in high-risk group
Endpoint domain: Mortality/survival
Primary endpoint: Inhibition of prostate cancer progression
Endpoint domain: Mortality/survival
Primary endpoint: Cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage increase in unhealthy snack choices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total caloric intake from snacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4 counts >350 cells/µl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sun protection behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin color
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Remission rate as defined by YBOCS score of 12 or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved postoperative physical well-being
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Decreased need for perioperative analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean marginal gaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sleep quality (PSQI total scores)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mood (PHQ-8 scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ever use of e-cigarettes
Endpoint domain: Adverse events/effects
Primary endpoint: Past month use of e-cigarettes
Endpoint domain: Adverse events/effects
Primary endpoint: Intentions to quit smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TGF-beta 1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Usefulness of VR trainer for training endoscopic techniques
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Training effect for hand-eye coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft epithelium aspect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical downstaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological downgrading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of tumor cells in the surgical specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: cognitive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Insomnia Severity Index (ISI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GRID-HAMD scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency of attending physician face-to-face response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay (LOS) for patients with SAH and brain trauma
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ICU cost savings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalent HIV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean 24‐h post‐transfusion survival
Endpoint domain: Mortality/survival
Primary endpoint: total insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: first phase of insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of maternal fever
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of hypoxaemic events
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of isolated neck failure
Endpoint domain: Mortality/survival
Primary endpoint: Urinary protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary TGF‐beta1 excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sensitivity of PCR test compared to culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increased breakpoint postprandially
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chance to gain and preserve Clinical Root Coverage (CRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Keratinized Tissue (KT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of death associated with BARC bleeding
Endpoint domain: Mortality/survival
Primary endpoint: PIVKA-II levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fruit and vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C-peptide secretion response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Median time to delivery of all doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical dosing errors
Endpoint domain: Adverse events/effects
Primary endpoint: VCSS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AVVQ improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: recurrence rate of VVS
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic levels of IL‐1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Systemic levels of IL‐10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DHA Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to last detectable DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of PCP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prolonged survival
Endpoint domain: Mortality/survival
Primary endpoint: Alleviation of DH at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum malondialdehyde (MDA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tei index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Superoxide dismutase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive function improvement (MMSE scores)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: breast cancer incidence
Endpoint domain: Mortality/survival
Primary endpoint: Iron absorption improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SFFR reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes